Novartis, Kendle, Cambrex, Chiltern, Parexel and SRI International - People on the move
have all had people on the move in the world of pharmaceutical
outsourcing.
After finally offloading tow of its pharmaceutical businesses to Lonza last week, Cambrex has announced a new senior leadership team under the continued leadership of the current chairman president and chief executive officer (CEO), James Mack.
Steven Klosk has been named executive vice president and chief operating officer (COO); Gregory Sargen has assumed the role of vice president and chief financial officer (CFO); while Luke Beshar is now the executive vice president of Strategy & Corporate Development.
Klosk previously held the same roles in the divested Biopharma business as well as Cambrex Pharma. Sargen served as vice president of finance for Cambrex, while Beshar was executive vice president and CFO.
Meanwhile, Thomas Bird, the current vice president of Corporate Development, will be leaving the company at the end of February to "pursue other interests."
Chiltern International has also made a series of appointments lately. In the US, Dr. James Esinhart now holds the role of global head of Biometrics.
In the UK, Gillian Reid has joined the CRO as key account director and senior business development executive, Stuart Young is now the global head of Clinical Monitoring and Aize Smink has joined as global head of Project Management.
In the past week, Novartis has also lost its vice president of Advanced Clinical Systems, Sylva Collins, to contract research organisation (CRO) Kendle, where she now serves as Vice President of Global Biometrics.
Based in the US, Collins will have the immediate task of standardising the CRO on one or two electronic data capture (EDC) systems instead of the multiple systems it currently uses. Other responsibilities include global biostatistics, data management, and scientific programming. She will also provide leadership to data centres in the US, Europe, Australia, and Mexico.
Parexel International has appointed George Mills to the position of vice president, Medical Imaging Consulting for Perceptive Informatics, a subsidiary of Parexel. He will advise biopharma clients on how to use medical imaging in support of regulatory submissions.
Mills is a former US Food and Drug Administration (FDA) employee who worked as Division Director of Medical Imaging and Haematology Products in the Office of Oncology Drug Products, part of the Center for Drug Evaluation and Research (CDER).
Meanwhile, non-profit CRO SRI International has announced the appointment of Caroline Satyadi as manager of operations for Quality Clinical Labs (QCL) in California, the company SRI acquired in April last year.
And across the border in Montreal, Canada, Fraser Day has been named vice president of business development for CIRION and will oversee and manage the global business and development functions for the central laboratory, research & development and validation services the company offers.
